BeOne Medicines (ONC) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Royalty Pharma (RPRX) has outperformed BeOne Medicines (ONC) over the past year, gaining 57.2% versus a gain of 6.6%. Over five years, RPRX leads with a +47.9% price change compared with +1.6% for ONC. BeOne Medicines is the larger company by market cap ($39.83 billion vs $32.48 billion), about 1.2 times the size.
On valuation, Royalty Pharma trades at a lower forward P/E (9.8x vs 34.2x for BeOne Medicines). Royalty Pharma pays a dividend yielding 1.62%, while BeOne Medicines does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | RPRX |
|---|---|---|
| Share price | $350.13 | $56.21 |
| Market cap | $39.83B | $32.48B |
| 1-day change | -3.82% | -0.97% |
| YTD return | +19.82% | +46.89% |
| 1-year return | +6.56% | +57.23% |
| 5-year return | +1.56% | +47.85% |
| P/E ratio (TTM) | 62.64 | 29.90 |
| Forward P/E | 34.15 | 9.80 |
| EPS (TTM) | $5.59 | $1.88 |
| Dividend yield | 0.00% | 1.62% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $5.34B | $2.38B |
| Revenue growth (YoY) | +40.23% | +5.06% |
| Net income (latest FY) | $286.93M | $770.95M |
| Gross margin | 87.49% | — |
| Operating margin | 8.37% | 65.58% |
| Net margin | 5.37% | 32.42% |
| 52-week high | $385.22 | $64.38 |
| 52-week low | $253.95 | $35.23 |
| Distance from 52-week high | -9.11% | -12.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.30% | +16.31% |
| Average volume | 388.88K | 2.93M |
| Shares outstanding | 104.92M | 445.28M |
| Employees | 12,000 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed ONC by 50.7 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (62.6x vs 29.9x trailing P/E).
- Royalty Pharma offers a meaningfully higher dividend yield (1.62% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +5.06%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ONC vs RPRX FAQ
Which is bigger, BeOne Medicines or Royalty Pharma?
BeOne Medicines (ONC) is larger, with a market capitalization of $39.83B compared with $32.48B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, ONC or RPRX?
RPRX returned +57.23% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ONC or RPRX?
RPRX has the lower trailing P/E at 29.9, versus 62.6 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BeOne Medicines or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.62%, while BeOne Medicines does not currently pay a regular dividend.
Are BeOne Medicines and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.